Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder

BACKGROUND: The short-term safety profile of once-daily valbenazine (NBI-98854) has been evaluated in several double-blind, placebo-controlled (DBPC) trials in adults with tardive dyskinesia (TD) who had a diagnosis of schizophrenia/schizoaffective (SCHZ) disorder or mood disorder. Studies with long...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Psychopharmacol Bull
Päätekijät: Josiassen, Richard C., Kane, John M., Liang, Grace S., Burke, Joshua, O’Brien, Christopher F.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: MedWorks Media Global 2017
Aiheet:
Original Presentations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5546552/
https://ncbi.nlm.nih.gov/pubmed/28839341
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia